Navigation Links
Cogdell Spencer Inc. Announces Increased Earnings in 2008, Cautious Outlook for 2009
Date:2/25/2009

/b>

On December 29, 2008, the Company announced that its Board of Directors approved a business plan for 2009 that focuses on cost reductions and the preservation of capital for productive deployment while allowing the Company to pursue its integrated delivery strategy despite client-related project delays resulting from the current financial crisis. As part of this plan, the Company has implemented a cost saving plan which, when combined with a reduction in force, will generate approximately $17 million in annual savings. As a part of this effort, the Company's Erdman subsidiary implemented a reduction in force in order to right-size the organization for contracted 2009 revenues, and eliminated approximately 115 jobs.

The Company also announced a reduction of its dividend from an annual equivalent of $1.40 per share and operating partnership unit ($0.35 per share and operating partnership unit per quarter) to an annual equivalent of $0.90 per share and operating partnership unit ($0.225 per share and operating partnership unit per quarter beginning with the fourth quarter of 2008).

Financing

In December 2008, the Company placed a mortgage on the previously unencumbered East Jefferson Medical Plaza, LLC facility in Metairie, LA. The $11.6 million note payable matures on January 31, 2012, and requires interest-only payments at an interest rate that has been swapped to a fixed rate of 5.55%.

In December 2008, the Company refinanced the mortgage note payable for the River Hills Medical Associates, LLC facility in Little River, SC. Terms of the note payable require monthly payments of principal and interest through December 2011, at which time the remaining principal is due. The note payable has an interest rate that has been swapped to a fixed rate of 5.53%. In connection with the refinancing, the principal balance was increased by $1.1 million to $4.0 million.


'/>"/>
SOURCE Cogdell Spencer Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Cogdell Spencer Inc. Acquires Summit Professional Plaza I and II in Brunswick, Georgia
2. Cogdell Spencer Inc. Reports Third Quarter 2007 Financial Results
3. Cogdell Spencer Announces a $100 Million Development at St. Lukes Riverside Outpatient Campus In Bethlehem, Pennsylvania
4. Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates
5. Cogdell Spencer Inc. Announces the Closing of the Marshall Erdman and Associates Merger
6. Cogdell Spencer Inc. Announces First Quarter Earnings Release and Conference Call Notice
7. Cogdell Spencer Inc. Reports First Quarter 2008 Financial Results
8. Cogdell Spencer Announces First Synergy Project in Pensacola, Florida
9. Cogdell Spencer Inc. Reports Third Quarter 2008 Financial Results
10. Cogdell Spencer Inc. Declares Quarterly Dividend and Outlines 2009 Business Strategy
11. Cogdell Memorial Hospital Partners with Healthcare Management Systems
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3ASTRO Gildas Club Chicago join to promote cancer survivorship 59515 1Biomedical Research Centre searches for immunological biomarkers 59513 1Biomedical Research Centre searches for immunological biomarkers 59513 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 1KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 3KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 4